Summit Therapeutics Inc.
SMMT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $12,825,975 | $1,617,276 | $821,678 | $248,123 |
| - Cash | $104,862 | $71,425 | $348,607 | $71,791 |
| + Debt | $7,218 | $106,099 | $518,763 | $2,782 |
| Enterprise Value | $12,728,331 | $1,651,950 | $991,834 | $179,114 |
| Revenue | $0 | $0 | $704 | $1,809 |
| % Growth | – | -100% | -61.1% | – |
| Gross Profit | -$15,007 | -$2,050 | -$1,810 | $1,809 |
| % Margin | – | – | -257% | 100% |
| EBITDA | -$212,853 | -$69,451 | -$73,118 | -$85,905 |
| % Margin | – | – | -10,381.7% | -4,748.8% |
| Net Income | -$221,315 | -$614,928 | -$78,782 | -$88,602 |
| % Margin | – | – | -11,185.9% | -4,897.8% |
| EPS Diluted | -0.31 | -0.99 | -0.38 | -0.96 |
| % Growth | 68.7% | -160.5% | 60.4% | – |
| Operating Cash Flow | -$142,106 | -$76,760 | -$41,582 | -$72,587 |
| Capital Expenditures | -$139 | -$128 | -$624 | -$306 |
| Free Cash Flow | -$142,245 | -$76,888 | -$42,206 | -$72,893 |